BACKGROUND: The aim of this study was to assess the physical performance and psychosocial status of lung cancer patients. PATIENTS AND METHODS: Patients with predominantly advanced-stage non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) were recruited. Muscle strength was assessed via hand-held dynamometry (HHD) and endurance capacity via the 6-minute walk test (6MWT), and results were compared to healthy reference values. Psychosocial status, lung cancer-specific symptoms, and quality of life (QoL) outcomes were evaluated. RESULTS: 39 patients (NSCLC n = 22, SCLC n = 17) with predominantly advanced-stage disease and a median age of 62 years (range 44-83 years) were enrolled. Compared to a healthy reference population, mean muscle strength values of upper (elbow flexion -28.2% (±17.5), elbow extension -12.4% (±11.1)) and lower (knee extension -47.6% (±19.3), hip abduction -44.9% (±14.9), hip flexion -13% (±24.2)) extremities, and 6MWT were lower (male/female: 434/411 m vs. 597/514 m). Lung cancer-specific symptoms and QoL were comparable to published data. CONCLUSION: Our results indicate that lung cancer patients experience muscular weakness, lower endurance performance, and decreased QoL compared to a healthy reference population. The feasibility and benefit of a structured exercise intervention in this specific population need to be evaluated, in particular its effect on psychosocial well-being.
BACKGROUND: The aim of this study was to assess the physical performance and psychosocial status of lung cancerpatients. PATIENTS AND METHODS: Patients with predominantly advanced-stage non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) were recruited. Muscle strength was assessed via hand-held dynamometry (HHD) and endurance capacity via the 6-minute walk test (6MWT), and results were compared to healthy reference values. Psychosocial status, lung cancer-specific symptoms, and quality of life (QoL) outcomes were evaluated. RESULTS: 39 patients (NSCLC n = 22, SCLC n = 17) with predominantly advanced-stage disease and a median age of 62 years (range 44-83 years) were enrolled. Compared to a healthy reference population, mean muscle strength values of upper (elbow flexion -28.2% (±17.5), elbow extension -12.4% (±11.1)) and lower (knee extension -47.6% (±19.3), hip abduction -44.9% (±14.9), hip flexion -13% (±24.2)) extremities, and 6MWT were lower (male/female: 434/411 m vs. 597/514 m). Lung cancer-specific symptoms and QoL were comparable to published data. CONCLUSION: Our results indicate that lung cancerpatients experience muscular weakness, lower endurance performance, and decreased QoL compared to a healthy reference population. The feasibility and benefit of a structured exercise intervention in this specific population need to be evaluated, in particular its effect on psychosocial well-being.
Authors: Dorothea Clauss; Christine Tjaden; Thilo Hackert; Lutz Schneider; Cornelia M Ulrich; Joachim Wiskemann; Karen Steindorf Journal: Support Care Cancer Date: 2017-04-17 Impact factor: 3.603
Authors: Christina Titz; Simone Hummler; Martina E Schmidt; Michael Thomas; Martin Steins; Joachim Wiskemann Journal: Support Care Cancer Date: 2018-02-26 Impact factor: 3.603
Authors: Joachim Wiskemann; Simone Hummler; Christina Diepold; Melanie Keil; Ulrich Abel; Karen Steindorf; Philipp Beckhove; Cornelia M Ulrich; Martin Steins; Michael Thomas Journal: BMC Cancer Date: 2016-07-19 Impact factor: 4.430
Authors: Oliver Klassen; Martina E Schmidt; Cornelia M Ulrich; Andreas Schneeweiss; Karin Potthoff; Karen Steindorf; Joachim Wiskemann Journal: J Cachexia Sarcopenia Muscle Date: 2016-11-28 Impact factor: 12.910
Authors: S M L M Looijaard; M S Slee-Valentijn; L N Groeneveldt; D J H Deeg; M Huisman; A B Maier Journal: BMC Geriatr Date: 2018-07-18 Impact factor: 3.921
Authors: Nichola Gale; David Wasley; Sioned Roberts; Karianne Backx; Annemarie Nelson; Robert van Deursen; Anthony Byrne Journal: Support Care Cancer Date: 2018-06-02 Impact factor: 3.603
Authors: Karin J C Sanders; Anita E M Kneppers; Coby van de Bool; Ramon C J Langen; Annemie M W J Schols Journal: J Cachexia Sarcopenia Muscle Date: 2015-09-07 Impact factor: 12.910